EntryPoint Capital LLC Buys 36,045 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR)

EntryPoint Capital LLC grew its position in Larimar Therapeutics, Inc. (NASDAQ:LRMR) by 197.7% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 54,281 shares of the company’s stock after acquiring an additional 36,045 shares during the period. EntryPoint Capital LLC’s holdings in Larimar Therapeutics were worth $210,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. Janus Henderson Group PLC raised its position in Larimar Therapeutics by 27.2% in the third quarter. Janus Henderson Group PLC now owns 5,566,855 shares of the company’s stock valued at $36,379,000 after purchasing an additional 1,189,467 shares during the last quarter. Sphera Funds Management LTD. raised its holdings in Larimar Therapeutics by 32.6% in the 3rd quarter. Sphera Funds Management LTD. now owns 414,478 shares of the company’s stock valued at $2,715,000 after buying an additional 102,009 shares during the last quarter. Jane Street Group LLC boosted its position in Larimar Therapeutics by 80.1% during the 3rd quarter. Jane Street Group LLC now owns 113,783 shares of the company’s stock worth $745,000 after buying an additional 50,622 shares during the period. Wellington Management Group LLP boosted its position in Larimar Therapeutics by 152.5% during the 3rd quarter. Wellington Management Group LLP now owns 105,246 shares of the company’s stock worth $689,000 after buying an additional 63,563 shares during the period. Finally, Barclays PLC grew its holdings in Larimar Therapeutics by 321.2% during the 3rd quarter. Barclays PLC now owns 60,032 shares of the company’s stock worth $393,000 after acquiring an additional 45,781 shares during the last quarter. Institutional investors and hedge funds own 91.92% of the company’s stock.

Larimar Therapeutics Stock Performance

Shares of LRMR stock opened at $2.35 on Friday. Larimar Therapeutics, Inc. has a fifty-two week low of $2.19 and a fifty-two week high of $11.20. The stock has a 50 day simple moving average of $3.08 and a two-hundred day simple moving average of $5.10. The company has a market cap of $149.95 million, a P/E ratio of -2.04 and a beta of 0.99.

Larimar Therapeutics (NASDAQ:LRMR) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.16). On average, research analysts predict that Larimar Therapeutics, Inc. will post -1.15 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on LRMR shares. Guggenheim reiterated a “buy” rating and set a $26.00 price target on shares of Larimar Therapeutics in a report on Tuesday, March 25th. Truist Financial assumed coverage on Larimar Therapeutics in a report on Wednesday, January 29th. They set a “buy” rating and a $18.00 target price on the stock. HC Wainwright increased their price target on Larimar Therapeutics from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Tuesday, March 25th. Finally, Robert W. Baird cut their price objective on Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 25th. Eleven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Larimar Therapeutics has an average rating of “Buy” and an average price target of $20.22.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.